{"database": "lobbying", "table": "lobbying_activities", "rows": [[1452740, "71f42eef-3ba5-418c-9121-6e02f5cf824e", "Q3", "THE DUBERSTEIN GROUP INC.", 12675, "PFIZER INC.", 2013, "third_quarter", "PHA", "Pharmaceutical issues, including track and trace legislation - HR 1919, Safeguarding America's Pharmaceuticals Act of 2013; S 957, Drug Supply Chain Security Act; HR 3204, Drug Quality and Security Act.\nSpecialty drug tiers - HR 460, Patients' Access to Treatments Act of 2013.Regulation of compounded drugs - HR 3019, S.A.F.E. Compounded Drugs Act of 2013; S 959, Pharmaceutical Quality, Security, and Accountability Act; HR 3204, Drug Quality and Security Act.", "HOUSE OF REPRESENTATIVES,SENATE", 100000, null, 0, 0, "2013-10-18T14:44:23.327000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1452740"], "units": {}, "query_ms": 11.43580803181976, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}